---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Limitations of current therapies"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Limitations of current therapies. Topics: Blood pressure control: NHANES August 2021 to August 2023, Blood pressure control: trends from 1999 to 2018, Blood pressure control and barriers to treatment: ICER assessment, Underuse of mineralocorticoid receptor antagonists in apparent treatment-resistant hypertension, and 12 further topics. 17 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Limitations of current therapies

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

### Summary

- Blood pressure control: In NHANES data from August 2021 to August 2023, 20.7% of US adults with hypertension had blood pressure controlled to less than 130/80 mm Hg, with no significant change from 2017 to March 2020 (22.2%). In a separate NHANES analysis, the age-adjusted proportion with controlled blood pressure declined from 53.8% in 2013 to 2014 to 43.7% in 2017 to 2018. ICER states that more than 70% of adults with hypertension remain above goal and names clinical inertia, pill burden, additive copays, variable tolerance of side effects, and low awareness as contributors.
- Underuse of aldosterone-targeted therapy: Among NHANES adults with apparent treatment-resistant hypertension, 8.3% were taking a mineralocorticoid receptor antagonist, rising from 6.3% in 2003 to 2004 to 13.3% in 2017 to 2020. Among US Veterans with apparent treatment-resistant hypertension, 4,277 (1.6%) were tested for primary aldosteronism, and testing was associated with a 4-fold higher likelihood of starting a mineralocorticoid receptor antagonist (hazard ratio 4.10).
- Tolerability of fourth-line options: The 2025 AHA/ACC guideline states that 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone because of hyperkalemia or antiandrogenic side effects, and that randomized trials have not demonstrated a reduction in home or 24-hour blood pressure with eplerenone at 25 to 100 mg daily compared with placebo. ICER reports gynecomastia rates of 3.9% to 6% with spironolactone in observational hypertension studies. Patient groups told ICER that clinicians are often reluctant to start spironolactone because of potential side effects. With baxdrostat, hyperkalemia led to discontinuation in 5.7% of participants in the BaxHTN long-term extension (safety data to 54 weeks), and serum potassium above 6 mmol/L occurred in 9.5% of the pooled baxdrostat arm and 0.8% of the placebo arm. Edema or fluid retention occurred in 9% of participants receiving aprocitentan at the approved 12.5 mg dose and 2% receiving placebo. ICER describes beta-blockers, alpha blockers, and central sympatholytic drugs as less efficacious and less well tolerated, and the guideline reserves renal denervation for adults with intolerable side effects to optimal drug regimens.
- Adherence and discontinuation: The weighted national nonadherence rate among 23.8 million adults with hypertension who filled antihypertensive prescriptions was 31.0%. A meta-analysis of 24 studies in apparent treatment-resistant hypertension estimated a pooled nonadherence prevalence of 31.2% (range 3.3% to 86.1%). Among Medicare beneficiaries starting antihypertensive treatment, discontinuation was 21.0% in 2007 and 21.3% in 2012, and low adherence fell from 37.4% in 2007 to 31.7% in 2012.
- Therapeutic inertia and access: ICER reports hearing that it often takes three to six months to adjust or add a medication in people with uncontrolled hypertension, and patients described readings above 140 mm Hg that were not acted on. The guideline links clinical inertia, among other factors, to the higher frequency of resistant hypertension in Black populations. Patients told ICER that prior authorization and step therapy can lead people to abandon treatment.

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm); [Muntner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489367/); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/); [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/); [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356); [Chang et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679429/); [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/); [Tajeu et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5215087/)

<a id="topic-2.2.2.1.9-2"></a>

### Blood pressure control: NHANES August 2021 to August 2023

> “About one-fifth of adults with hypertension had their blood pressure controlled (20.7%) to less than 130/80 mm Hg.”
> “No significant change was seen between 2017–March 2020 and August 2021–August 2023 in the prevalence of hypertension awareness (60.2% compared with 59.2%), treatment (50.3% and 51.2%), or control (22.2% and 20.7%) among adults with hypertension (Figure 5, Table 5).”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-2.2.2.1.9-3"></a>

### Blood pressure control: trends from 1999 to 2018

> “the age-adjusted estimated proportion with controlled blood pressure increased from 31.8% in 1999-2000 to 48.5% in 2007-2008, remained stable through 2013-2014 (53.8%), and then declined to 43.7% in 2017-2018.”

Source: [Muntner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489367/)

<a id="topic-2.2.2.1.9-4"></a>

### Blood pressure control and barriers to treatment: ICER assessment

> “Although decreasing blood pressure has been associated with improved outcomes, more than 70% of adults with hypertension continue to have a blood pressure above goal”
> “Clinical inertia, pill burden, additive copays for multiple medications, variable tolerance for side effects, and a lack of awareness of the importance of treating hypertension can make treatment challenging.”
> “one survey of US adults showed that 31% were non-adherent to medications”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.9-5"></a>

### Underuse of mineralocorticoid receptor antagonists in apparent treatment-resistant hypertension

> “Among those with aTRH, 84.3% were on ACE inhibitors/ARBs, 72.1% on thiazide diuretics, 55.4% on calcium channel blockers, 32.3% on a loop diuretic and 8.3% on mineralocorticoid receptor antagonists (MRA).”
> “Among adults with aTRH, utilization of MRAs increased over time from 6.3% in 2003–2004 to 13.3% in 2017–2020.”
> “less than 1 in 5 adults with aTRH were prescribed an MRA despite high quality evidence supporting its use.”
> “Limited adaption could be related to the above issues or concerns specific to MRA use such as hyperkalemia, the need for routine monitoring of labs or concerns about renal dysfunction.”

Source: [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/)

<a id="topic-2.2.2.1.9-6"></a>

### Underuse of aldosterone-targeted therapy: lorundrostat phase 3 trial report

> “However, aldosterone-targeted antihypertensive medication is underused worldwide in the treatment of hypertension.”
> “However, MRAs are underused due to safety concerns with hyperkalemia and, in the case of spironolactone, chemotype-specific androgenic effects.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.2.2.1.9-7"></a>

### Primary aldosteronism testing and mineralocorticoid receptor antagonist initiation

> “4277 (1.6%) patients who were tested for primary aldosteronism were identified.”
> “Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time.”

Source: [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/)

<a id="topic-2.2.2.1.9-8"></a>

### Spironolactone and eplerenone intolerance and efficacy: guideline

> “Nevertheless, 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone due to hyperkalemia or antiandrogenic side effects.”
> “Eplerenone, a more selective steroidal MRA that avoids the antiandrogenic side effects but may cause hyperkalemia, is a potential alternative to spironolactone, but RCTs have not demonstrated reduction of home BP or 24-hour BP at doses between 25 and 100 mg daily when compared with placebo, and effective treatment may require higher dosages.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.9-9"></a>

### Hyperkalemia and gynecomastia with mineralocorticoid receptor antagonists

> “However, use of MRA medications is often limited by side effects, most prominently hyperkalemia and gynecomastia.”
> “In observational studies evaluating treatment for hypertension with spironolactone, gynecomastia rates ranged between 3.9 to 6%”
> “For people with apparent treatment-resistant hypertension who are already taking three or more antihypertensive medications and are not at their goal blood pressure, fourth-line options may be limited by side effects such as hyperkalemia and gynecomastia.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “MRAs are known to be effective in lowering BP; however, they have demonstrated side effects that have limited their use.”
> “Specifically, spironolactone, the most commonly prescribed MRA, is known for inducing hyperkalemia as well as gynecomastia in men and fertility issues in women.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.2.2.1.9-10"></a>

### Clinician reluctance to start spironolactone: patient and clinician input to ICER

> “Additionally, patient groups mentioned that clinicians are often reluctant to start a fourth-line medication like spironolactone because of potential side effects”
> “For such individuals, mineralocorticoid receptor antagonists such as spironolactone are the preferred option; however, spironolactone may be difficult to take due to side effects, particularly for men.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.9-11"></a>

### Aldosterone synthase inhibitors: hyperkalemia with baxdrostat

> “In the long-term extension of the BaxHTN trial, with safety data to 54 weeks, hyperkalemia led to treatment discontinuation in 5.7% of those in the pooled baxdrostat arm (1 mg and 2 mg),”
> “serum potassium levels greater than 6 mmol/L were reported in 9.5% of those in the pooled baxdrostat arm, and 0.8% of those in the placebo arm.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.9-12"></a>

### Other fourth-line and add-on options: efficacy and tolerability

> “While there are alternative antihypertensive medications beyond MRAs, many of the other classes of agents (e.g., beta-blockers, alpha blockers, central sympatholytic drugs) tend to be less efficacious and less well-tolerated.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Aprocitentan has not been directly compared with spironolactone in the treatment of resistant hypertension and edema/fluid retention occurred in 9% at 12.5 mg (FDA–approved dose) versus 18% at 25 mg (unapproved dose) and 2% with placebo”
> “Given the modest BP-lowering effects of RDN over the sham arm or addition of spironolactone, RDN should be reserved for adults with hypertension who develop intolerable side effects to optimal antihypertensive regimens.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.9-13"></a>

### Medication nonadherence: insured US adults, 2015

> “We included 23.8 million hypertensive adults who filled 265.8 million prescriptions for antihypertensive medications.”
> “The overall weighted national nonadherence rate was 31.0%, with greater nonadherence among women versus men, younger versus older adults (aged 18-34 years, 58.1%; aged 65-74 years, 24.4%), fixed-dose combination medication nonusers (31.2%) versus users (29.4%), and by pharmacy outlet type (retail only, 30.7%; any mail order, 19.8%).”

Source: [Chang et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679429/)

<a id="topic-2.2.2.1.9-14"></a>

### Medication nonadherence: apparent treatment-resistant hypertension

> “From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.”
> “By using a random effects model, the pooled prevalence of nonadherence was 31.2%”
> “with nonadherence rates ranging from 3.3 to 86.1%.”

Source: [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/)

<a id="topic-2.2.2.1.9-15"></a>

### Discontinuation and low adherence after treatment initiation: Medicare beneficiaries

> “Between 2007 and 2012, 41,135 Medicare beneficiaries in the 5% sample initiated antihypertensive medication.”
> “Discontinuation was stable over the study period (21.0% in 2007 and 21.3% in 2012; p-trend=0.451).”
> “Low adherence decreased from 37.4% in 2007 to 31.7% in 2012 (p-trend<0.001).”

Source: [Tajeu et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5215087/)

<a id="topic-2.2.2.1.9-16"></a>

### Therapeutic inertia

> “We also heard that there is clinical inertia when managing blood pressure and that it often takes three to six months to adjust or add a blood pressure medication, even in people with uncontrolled hypertension.”
> “We also heard that clinical inertia could result in suboptimal treatment of hypertension.”
> “For example, people living with hypertension told us that they had systolic blood pressure readings above 140 mm Hg at appointments, but their clinicians either did not address the reading and intensify therapy or told them that they did not need additional therapy.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Resistant hypertension is more common in Black populations, which may be related to adverse social factors, including living in a professional shortage area or disadvantaged neighborhood and clinical inertia.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.9-17"></a>

### Insurance coverage barriers

> “We heard that insurance coverage barriers, such as prior authorization and step therapy, can place a high burden on patients and can cause people to abandon treatment.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
